Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer

Marilyn L. Kwan, Janise M. Roh, Cecile A. Laurent, Jean Lee, Li Tang, Dawn Hershman, Lawrence H. Kushi, Song Yao

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Breast cancer patients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa. Methods: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014. Results: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45%) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27%) switchers within the first year. After the switch, 136 (47%) AI switchers and 260 (58%) TAM switchers finished or remained on the planned therapy; 69 (24%) AI switchers and 99 (22%) TAM switchers discontinued therapy. AI side effects (73%), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42%). Conclusions: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalCancer Causes and Control
DOIs
StateAccepted/In press - Mar 27 2017
Externally publishedYes

Fingerprint

Immunoglobulin Class Switching
Aromatase Inhibitors
Tamoxifen
Breast Neoplasms
Therapeutics
Arthralgia
Prescriptions
Hormones
Bone and Bones

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Cancer survivor
  • Cohort study
  • Hormonal therapy
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kwan, M. L., Roh, J. M., Laurent, C. A., Lee, J., Tang, L., Hershman, D., ... Yao, S. (Accepted/In press). Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes and Control, 1-6. https://doi.org/10.1007/s10552-017-0888-9

Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. / Kwan, Marilyn L.; Roh, Janise M.; Laurent, Cecile A.; Lee, Jean; Tang, Li; Hershman, Dawn; Kushi, Lawrence H.; Yao, Song.

In: Cancer Causes and Control, 27.03.2017, p. 1-6.

Research output: Contribution to journalArticle

Kwan, Marilyn L. ; Roh, Janise M. ; Laurent, Cecile A. ; Lee, Jean ; Tang, Li ; Hershman, Dawn ; Kushi, Lawrence H. ; Yao, Song. / Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. In: Cancer Causes and Control. 2017 ; pp. 1-6.
@article{7942d259fd044b0ea88167bdcb43c2a9,
title = "Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer",
abstract = "Purpose: Breast cancer patients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa. Methods: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014. Results: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45{\%}) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27{\%}) switchers within the first year. After the switch, 136 (47{\%}) AI switchers and 260 (58{\%}) TAM switchers finished or remained on the planned therapy; 69 (24{\%}) AI switchers and 99 (22{\%}) TAM switchers discontinued therapy. AI side effects (73{\%}), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42{\%}). Conclusions: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.",
keywords = "Aromatase inhibitors, Breast cancer, Cancer survivor, Cohort study, Hormonal therapy, Tamoxifen",
author = "Kwan, {Marilyn L.} and Roh, {Janise M.} and Laurent, {Cecile A.} and Jean Lee and Li Tang and Dawn Hershman and Kushi, {Lawrence H.} and Song Yao",
year = "2017",
month = "3",
day = "27",
doi = "10.1007/s10552-017-0888-9",
language = "English (US)",
pages = "1--6",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer

AU - Kwan, Marilyn L.

AU - Roh, Janise M.

AU - Laurent, Cecile A.

AU - Lee, Jean

AU - Tang, Li

AU - Hershman, Dawn

AU - Kushi, Lawrence H.

AU - Yao, Song

PY - 2017/3/27

Y1 - 2017/3/27

N2 - Purpose: Breast cancer patients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa. Methods: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014. Results: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45%) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27%) switchers within the first year. After the switch, 136 (47%) AI switchers and 260 (58%) TAM switchers finished or remained on the planned therapy; 69 (24%) AI switchers and 99 (22%) TAM switchers discontinued therapy. AI side effects (73%), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42%). Conclusions: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.

AB - Purpose: Breast cancer patients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa. Methods: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014. Results: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45%) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27%) switchers within the first year. After the switch, 136 (47%) AI switchers and 260 (58%) TAM switchers finished or remained on the planned therapy; 69 (24%) AI switchers and 99 (22%) TAM switchers discontinued therapy. AI side effects (73%), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42%). Conclusions: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Cancer survivor

KW - Cohort study

KW - Hormonal therapy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85016125809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016125809&partnerID=8YFLogxK

U2 - 10.1007/s10552-017-0888-9

DO - 10.1007/s10552-017-0888-9

M3 - Article

SP - 1

EP - 6

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

ER -